GlassScriptPhysician profile
Lisa M Knight
NPI 1235213935
$3,299.71
in general payments reported to CMS, 2019-2025
28 companies · $2,045 in 2025
The $2,045 reported for 2025 was more than what 76% of Pediatric Endocrinology providers received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25.12 · 2021: $90.78 · 2022: $69.92 · 2023: $235 · 2024: $834 · 2025: $2,045.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,800 · Food and Beverage: $1,314.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,800.00 |
| Food and Beverage | $1,313.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Azurity Pharmaceuticals, INC. | $1,848.18 | 2023-2025 | Triptodur, Triptodur |
| Insulet Corporation | $245.92 | 2022-2025 | Omnipod |
| Novo Nordisk INC | $150.77 | 2025 | Ozempic, Wegovy |
| Kyowa Kirin, INC. | $138.80 | 2023-2024 | Crysvita |
| Abbvie INC. | $125.44 | 2021-2025 | |
| Ascendis Pharma Endocrinology INC | $72.70 | 2023-2025 | Skytrofa |
| Rhythm Pharmaceuticals, INC. | $70.19 | 2022-2024 | Imcivree, Imcivree |
| Abbott Laboratories | $69.50 | 2022-2025 | Freestyle Libre 3 |
| Beta Bionics, INC. | $64.05 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Pfizer INC. | $49.09 | 2024-2025 | |
| Endo USA, INC. | $48.62 | 2024-2025 | Supprelin |
| Endo Pharmaceuticals INC. | $45.56 | 2019-2024 | Supprelin |
| Dexcom, INC. | $42.27 | 2024-2025 | Dexcom G6 Transmitter |
| Tandem Diabetes Care, INC. | $42.01 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Xeris Pharmaceuticals, INC. | $40.19 | 2024-2025 | Gvoke Hypopen |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eton Pharmaceuticals, INC. | $37.80 | 2024-2025 | Alkindi, Increlex, Khindivi |
| Biomarin Pharmaceutical INC. | $33.11 | 2023-2025 | Voxzogo 1.2mg |
| Amphastar Pharmaceuticals, INC. | $23.83 | 2024 | Baqsimi |
| Neurocrine Biosciences, INC. | $23.49 | 2025 | |
| Lilly USA, LLC | $21.71 | 2023 | Lyumjev, Baqsimi |
| Sanofi-Aventis U.S. LLC | $19.78 | 2023 | |
| Averitas Pharma INC. | $16.50 | 2025 | Qutenza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.07 | 2021 | |
| Tolmar, INC. | $15.84 | 2024 | |
| Ultragenyx Pharmaceutical INC. | $13.46 | 2021 | |
| Medtronic Minimed, INC. | $12.55 | 2019 | |
| Medtronic, INC. | $12.28 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Knight listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.